NCT02842203Active, not recruiting
Use of ctDNA for Monitoring of Stage III Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 137 (actual)
- First submitted
- 20 Jul 2016
- Start date
- Sept 2016
- Primary completion date
- Sept 2027
- Lead sponsor
- University of Pittsburgh
- Diseases
- Colorectal cancer
- NCT number
- NCT02842203
What you commit to
- Study type: Observational
- Participants enrolled: 137
- From Sept 2016 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Blood sampling would compromise patients overall health such as presence of severe anemia
- Unable to give informed consent
Who the study is looking for
- Men and women with CRC Stage III A, B, or C
- Age ≥18 years
- Willingness to provide blood samples for research purposes
- Ability to understand written informed consent document, and written informed consent provided
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Medical Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.